Free tool
Drug Trial Radar: Endocrinology and women's health
Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
8
Recruiting, industry sponsors, Endocrinology and women's health, Phase 3
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed328
8 trials
Showing 1 to 8, recently updated first.
- A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin AnalogsPivotal-lookingRecruiting
Debiopharm International SAIndustry
NCT06930625 · 119 participants (planned) · Start Nov 26, 2025 · Primary completion Jun 2028
Drug: Debio 4126; Placebo · For: Acromegaly
Sites: Los Angeles, California; Chicago, Illinois; Boston, Massachusetts · 74 sites in all
- A Study to Confirm if Fezolinetant Helps to Reduce Hot Flashes in Indian Women Going Through MenopausePivotal-lookingRecruiting
Astellas Pharma IncAstellas (ALPMY)
NCT07829653 · 100 participants (planned) · Start Oct 23, 2026 · Primary completion Mar 31, 2028
Drug: Fezolinetant · For: Hot Flashes
Sites: Bengaluru, India
- Phase 3 Study of LUM-201 in Children With Growth Hormone DeficiencyPivotal-lookingRecruiting
Lumos PharmaIndustry
NCT06948214 · 150 participants (planned) · Start May 20, 2026 · Primary completion Dec 2027
Drug: LUM-201 · For: Growth Hormone Deficiency (GHD)
Sites: Birmingham, Alabama; Madera, California; Orange, California · 55 sites in all
- Evaluate the Efficacy and Safety of HMI-115 in Women With Moderate to Severe Endometriosis-associated PainPivotal-lookingRecruiting
Hope Medicine (Nanjing) Co., LtdIndustry
NCT07318688 · 540 participants (planned) · Start Jan 29, 2026 · Primary completion Mar 1, 2028
Drug: HMI-115; Placebo · For: Endometriosis
Sites: Beijing, China; Nanning, China; Suzhu, China · 5 sites in all
- An Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of North Star Desiccated Porcine Thyroid Extract Tablets.Pivotal-lookingRecruiting
Neuvosyn Laboratories, LLCIndustry
NCT07747103 · 466 participants (planned) · Start Jun 30, 2026 · Primary completion Nov 2027
Drug: Desiccated Porcine Thyroid Extract Tablets · For: Hypothyroidism
Sites: Modesto, California; Redding, California; San Diego, California · 25 sites in all
- GB06 Phase III Trial for Pediatric Growth Hormone DeficiencyPivotal-lookingRecruiting
Kexing Biopharm Co., Ltd.Industry
NCT07553351 · 192 participants (planned) · Start Jun 6, 2026 · Primary completion Jul 25, 2028
Drug: GB06; Norditropin®FlexProTM · For: Growth Hormone Deficiency (GHD); Growth Hormone Deficiency in Children; Growth Hormone Deficiency, Pediatric
Sites: Chengdu, China
- A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or EndometriosisPivotal-lookingRecruiting
Sumitomo Pharma Switzerland GmbHIndustry
NCT05862272 · 1,000 participants (planned) · Start Aug 14, 2023 · Primary completion Jul 2029
Drug: Relugolix Combination Tablet · For: Uterine Fibroids; Endometriosis
Sites: Mobile, Alabama; Chandler, Arizona; Mesa, Arizona · 120 sites in all
- A Comparative Study to Valuating the Efficacy and Safety of QL1206 and Prolia®Pivotal-lookingRecruiting
Qilu Pharmaceutical Co., Ltd.Industry
NCT07062978 · 278 participants (planned) · Start Jun 27, 2025 · Primary completion Jan 2027
Drug: QL1206; Prolia® · For: Postmenopausal Women With Osteoporosis at High Risk of Fracture
Sites: Guizhou, China
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.